These two volumes contain the proceedings of a 3 day international meeting held at the University of Cambidge and Queens' College Cambridge from 31st July to 2nd August 1985 on the Side-Effects of Anti-Inflammatory Analgesic Drugs. The first meeting was held in Verona, (Italy) in 1982 and the organisers felt that, with a number of recent developments including the withdrawal of a num ber of new anti-inflammatory drugs, and concern being expressed in the lay and specialist medical press and other media about the safety of these drugs, that it was appropriate to have a second such meeting. The meeting was attended by some 300 delegates and the dis cussion focussed most intently on the recent issues, e. g. the value of adverse drug reaction reporting of the non-steroidal anti inflammatory (NSAI) drugs, certain side-effects associated with particular NSAI drugs, the predictive value of animal models etc. Organising a meeting de novo without outside help would not have been possible without the immensely valuable help given en thusiastically by people and financial assistance given most generously by those pharmaceutical companies listed below. These financial contributions were given despite current economic dif ficulties and moves to restrict the proportion of profits towards educational activities.
Table of Contents1 Table of Contents.- Section I Clinical and Epidemiological Aspects.- 1 Introduction and historical aspects of the side-effects of anti-inflammatory analgesic drugs.- 2 Epidemiology in the United Kingdom of adverse drug reactions from non-steroidal anti-inflammatory drugs.- Discussion.- 3 Assessment of adverse reactions to NSAIDs: Pre- and post-marketing..- Discussion.- 4 Incidence of serious side effects from non-steroidal anti-inflammatory drugs (NSAIDs) in the USA.- Discussion.- 5 Trends and patterns in adverse drug reactions to non-steroidal anti-inflammatory drugs reported in Sweden.- Discussion.- 6 Rare adverse reactions to non-steroidal anti-inflammatory drugs.- Discussion.- 7 Pyrazolone-induced agranulocytosis: an epidemiological evaluation.- Discussion.- 8 Potential biases influencing interpretation of data from worldwide spontaneous ADR reports.- Discussion.- 9 Prescription-event monitoring of five non-steroidal anti-inflammatory drugs.- Discussion.- 10 Side-effects of non-steroidal anti-inflammatory drugs in children with juvenile rheumatoid arthritis.- Discussion.- 11 Non-steroidal anti-inflammatories: outpatient audit of patient preferences and side-effects in different diseases.- Discussion.- 12 Non-steroidal anti-inflammatories in the elderly.- Discussion.- 13 Ibuprofen overdose the first year following over-the-counter release.- Discussion.- Section II Drug Interactions and Drug Metabolism.- 14 Drug interactions between the anti-inflammatory drugs and with other agents.- Discussion.- 15 Interactions between non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors in man.- Discussion.- 16 Responders and non-responders to NSAI drug interactions a neglected problem?.- Discussion.- 17 Biological implications of the metabolic chiral inversion of 2-arylpropionic acid non-steroidal anti-inflammatory drugs.- Discussion.- 18 A medicinal chemist’s perspective of side-effects of anti-inflammatory analgesic drugs.- Discussion.- 19 Genetic and environmental aspects of drug metabolism relevant to side-effects in arthritic disease.- Discussion.- 20 Disease drug interactions: utility of the conditional concept for experimental pharmacology and toxicology in the context of inflammation.- Discussion.- 21 Pharmacokinetic profile of ketoprofen in elderly subjects.- 22 The effects of frusemide and Dorbanex on the pharmacokinetic profile of benoxaprofen in elderly subjects.- Discussion.- 23 Enantioselective dispositon of a model non-steroidal anti-inflammatory drug 2-phenylpropionic acid.- Section III Gastrointestinal Tract (Clinical Aspects).- 24 Anti-inflammatory drugs and upper gastrointestinal perforation.- Discussion.- 25 Piroxicam and gastrointestinal ulceration.- Discussion.- 26 Anti-inflammatory drugs and gastrointestinal disease. Reasons for the failure of adverse reaction reporting and surveillance systems to detect a significant association.- Discussion.- 27 An evaluation of the frequency of anti-inflammatory and analgesic drug intake among patients with acute gastrointestinal bleeding.